RNAM

Avidity Biosciences

Fundamental data last updated:March 2, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

74

Business Summary

Avidity Biosciences is a biotechnology company focused on developing RNA-based therapeutics. It works on advancing treatments designed to address serious diseases through targeted molecular approaches.

VALUATION

P/E

-

Market Cap ($M USD)

$11,246

Forward P/E

-

PEG

-

PRICE TO SALES

454.6

PRICE TO BOOK

6

EV / EBITDA

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$4.19

Next Year EPS Growth Estimate

-

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-29.10%

Operating Margin

-2934.90%

Debt-to-Equity

0

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Gainseekers Quantitative Analysis

Summary

Avidity Biosciences is a Nasdaq-listed biotechnology company with a market capitalization of $11,246 million. The company is currently unprofitable, reporting EPS of -$4.19, a return on equity of -29.10%, and an operating margin of -2934.90%. It trades at a very high Price/Sales ratio of 454.6 and a Price/Book ratio of 6, with its next earnings report expected in 74 days.

AI Exposure / Tech Reliance

As a biotechnology company within the healthcare sector, Avidity Biosciences relies heavily on advanced scientific and technical innovation to develop its therapeutic pipeline. Its value is closely tied to research-driven breakthroughs rather than current earnings generation.

The Bull Case

The company carries no debt, with a Debt/Equity ratio of 0, which provides financial flexibility. Additionally, the mean consensus target price of $73.83 suggests potential upside depending on clinical and operational progress.

The Bear Case

The company is deeply unprofitable, with negative EPS of -$4.19 and an operating margin of -2934.90%, indicating substantial ongoing losses. Its extremely high Price/Sales ratio of 454.6 may reflect elevated valuation risk relative to its current revenue base.

Market Sentiment & Smart Money

Short Interest %

-

Analyst Consensus

2.63

Average Analyst Price Target

$73.83

Institutional Ownership %

-

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low